Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 68071-2711

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-2711). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2711 9)

Label for Duloxetine Delayed-Release Capsules 20 mg by NuCare Pharmaceuticals, Inc., NDC 68071-2711-9. Contains 90 delayed-release capsules, each with 22.4 mg Duloxetine Hydrochloride USP equivalent to 20 mg Duloxetine. Includes manufacturer details and storage instructions with warnings to keep out of reach of children.*

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride, the active ingredient in Duloxetine Delayed-Release. The diagram shows the chemical bonds and rings characteristic of the compound, including a fused ring system and a thiophene ring.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph comparing the proportion of patients with relapse over time in days. It shows two treatment groups: placebo (dashed line) and duloxetine delayed-release capsules (solid line), indicating a lower relapse proportion with duloxetine over approximately 200 days from randomization.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier curve comparing the proportion of patients with relapse over time from randomization to relapse (days) between placebo and Duloxetine delayed-release capsules. The graph shows a higher relapse proportion in the placebo group versus the Duloxetine group throughout the study period up to approximately 250 days.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the percentage of patients improved against percent improvement in pain from baseline. It compares three doses of Duloxetine (60 mg BID, 60 mg QD, and 20 mg QD) with placebo. The graph illustrates how patient improvement percentages decrease as pain improvement percent increases, with placebo showing the lowest improvement overall.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: DUL 60mg BID, DUL 60mg QD, and Placebo, with the y-axis representing the percentage of patients improved (0-100%) and the x-axis showing percent improvement in pain from baseline (0 to 100%).*

FDA Label Image

Figure 5 (Duloxetine 06)

This line graph compares the percentage of patients improved versus percent improvement in pain from baseline for three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved, illustrating a higher improvement for both Duloxetine regimens compared to placebo.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. The chart shows declining percentages of patient improvement as pain improvement increases from 0 to 100%.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for placebo and Duloxetine 60/120 mg once daily groups. The graph shows a descending trend in patient improvement as percent improvement in pain increases for both groups.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline with two groups: placebo and Duloxetine 60 mg once daily (DUL). The x-axis shows percent improvement in pain (BOCF) from >0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. The Duloxetine line consistently shows higher patient improvement percentages than placebo across the range.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF), showing two groups: placebo and Duloxetine 60/120 mg once daily. The graph plots percent improvement in pain on the x-axis and percentage of patients improved on the y-axis, illustrating changes over the improvement scale from >0% to 100%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.